» Articles » PMID: 29998038

Prediction of Off-target Activities for the End-to-end Design of CRISPR Guide RNAs

Overview
Journal Nat Biomed Eng
Publisher Springer Nature
Date 2018 Jul 13
PMID 29998038
Citations 130
Authors
Affiliations
Soon will be listed here.
Abstract

The CRISPR-Cas9 system provides unprecedented genome editing capabilities. However, off-target effects lead to sub-optimal usage and additionally are a bottleneck in the development of therapeutic uses. Herein, we introduce the first machine learning-based approach to off-target prediction, yielding a state-of-the-art model for CRISPR-Cas9 that outperforms all other guide design services. Our approach, Elevation, consists of two interdependent machine learning models-one for scoring individual guide-target pairs, and another which aggregates these guide-target scores into a single, overall summary guide score. Through systematic investigation, we demonstrate that Elevation performs substantially better than competing approaches on both tasks. Additionally, we are the first to systematically evaluate approaches on the guide summary score problem; we show that the most widely-used method performs no better than random at times, whereas Elevation consistently outperformed it, sometimes by an order of magnitude. We also introduce an evaluation method that balances errors between active and inactive guides, thereby encapsulating a range of practical use cases; Elevation is consistently superior to other methods across the entire range. Finally, because of the large scale and computational demands of off-target prediction, we have developed a cloud-based service for quick retrieval. This service provides end-to-end guide design by also incorporating our previously reported on-target model, Azimuth. (https://crispr.ml:please treat this web site as confidential until publication).

Citing Articles

Transitioning from wet lab to artificial intelligence: a systematic review of AI predictors in CRISPR.

Abbasi A, Asim M, Dengel A J Transl Med. 2025; 23(1):153.

PMID: 39905452 PMC: 11796103. DOI: 10.1186/s12967-024-06013-w.


Appraisal of CRISPR Technology as an Innovative Screening to Therapeutic Toolkit for Genetic Disorders.

Shahid A, Zahra A, Aslam S, Shamim A, Ali W, Aslam B Mol Biotechnol. 2025; .

PMID: 39894889 DOI: 10.1007/s12033-025-01374-z.


A tool for CRISPR-Cas9 sgRNA evaluation based on computational models of gene expression.

Cohen S, Bergman S, Lynn N, Tuller T Genome Med. 2024; 16(1):152.

PMID: 39716183 PMC: 11668024. DOI: 10.1186/s13073-024-01420-6.


Crispr-SGRU: Prediction of CRISPR/Cas9 Off-Target Activities with Mismatches and Indels Using Stacked BiGRU.

Zhang G, Luo Y, Xie H, Dai Z Int J Mol Sci. 2024; 25(20).

PMID: 39456727 PMC: 11507390. DOI: 10.3390/ijms252010945.


The Evolution of Nucleic Acid-Based Diagnosis Methods from the (pre-)CRISPR to CRISPR era and the Associated Machine/Deep Learning Approaches in Relevant RNA Design.

Chakraborty S, Ray Dutta J, Ganesan R, Minary P Methods Mol Biol. 2024; 2847:241-300.

PMID: 39312149 DOI: 10.1007/978-1-0716-4079-1_17.


References
1.
Crosetto N, Mitra A, Silva M, Bienko M, Dojer N, Wang Q . Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nat Methods. 2013; 10(4):361-5. PMC: 3651036. DOI: 10.1038/nmeth.2408. View

2.
Tsai S, Zheng Z, Nguyen N, Liebers M, Topkar V, Thapar V . GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2014; 33(2):187-197. PMC: 4320685. DOI: 10.1038/nbt.3117. View

3.
Singh R, Kuscu C, Quinlan A, Qi Y, Adli M . Cas9-chromatin binding information enables more accurate CRISPR off-target prediction. Nucleic Acids Res. 2015; 43(18):e118. PMC: 4605288. DOI: 10.1093/nar/gkv575. View

4.
Aguirre A, Meyers R, Weir B, Vazquez F, Zhang C, Ben-David U . Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016; 6(8):914-29. PMC: 4972686. DOI: 10.1158/2159-8290.CD-16-0154. View

5.
Cradick T, Qiu P, Lee C, Fine E, Bao G . COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. Mol Ther Nucleic Acids. 2014; 3:e214. PMC: 4272406. DOI: 10.1038/mtna.2014.64. View